Hepatitis C Virus (HCV) Testing Market Outlook (2023 to 2033)

The global hepatitis C virus (HCV) testing market size is expected to accumulate US$ 785.3 million in value by 2023 end. During the forecast period ranging from 2023 to 2033, a CAGR worth 5.4% has been projected for the market, with an expected closing value worth US$ 1,326.7 million. From 2018 to 2022, the industry unfolded at a value CAGR worth 4.6%.

The growing burden of infectious diseases on the global healthcare system is a significant consideration, with developing countries bearing a disproportionate share of the burden. Over time, the burden of hepatitis C virus infection has accelerated. According to the Institute of Liver and Biliary Sciences India, around 3% of the world's population is infected with the hepatitis C virus.

In 80 percent of infected patients, HCV did cause chronic infection. Initial hepatitis C virus testing employs serological assays to detect antibodies against HCV in blood samples. According to the Centers for Disease Control and Prevention (CDC) guidelines for hepatitis C screening, a cut-off ratio for anti-HPV antibodies is added, which aids in the selection of additional assays for confirmation of screening results.

The Nucleic Acid Amplification Test (NAT) is used to confirm and determine viral load. Regarding all constructive HCV antibody tests, an RNA test is performed. HCV genotyping tests are used in clinical HPV management to determine viral load and optimal treatment duration. Also, the use of non-sterile needles for tattooing and body piercing is a common cause of hepatitis C virus infection spread.

Attributes Key Statistics
Global Market CAGR (2023 to 2033) 5.4%
Anticipated Market Value (2023) US$ 785.3 million
Global Market (2033) US$ 1,326.7 million
Global Market Attraction The rising prevalence of hepatitis C virus infection fueled by inadequate blood donation strategies

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Factors Spearheading the Global Hepatitis C Virus (HCV) Testing Market

The rising prevalence of hepatitis C virus infection is the primary driver of the global hepatitis C virus testing market. Inadequate blood donation strategies are the leading cause of hepatitis C virus infection. Also, hepatitis C screening is required before organ donation, and growing organ donation projects around the world are expected to drive future growth.

The introduction of point-of-care testing products for HCV testing raises the potential for HCV testing kits. The FDA approved the OraQuick HCV Rapid Antibody Test in 2010, and it is now widely used as an alternative to enzyme immunoassay testing for HCV. Also, the use of new electrochemical immuno-sensor and nano-sensor technologies in HPV testing is expected to change current practices.

Factors Stunting the Global Hepatitis C Virus (HCV) Testing Market

Factors that are limiting the adoption of hepatitis C virus testing include:

  • Insufficient insurance coverage for hepatitis C testing
  • Limited access to regular healthcare
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

North America Emerging as an Opportunistic Hepatitis C Virus (HCV) Testing Market

Country/ Region Market Share (2022)
North America 33.4%
The United States 29.5%

An estimated 12.5-40% of detained people in North America have HCV-antibody positivity, supporting the recommendation to screen this population for HCV infection and increasing market demand.

Infection with the Hepatitis C virus (HCV) is a leading cause of morbidity and mortality in the United States. HCV is primarily transmitted via parenteral exposure to infectious blood or body fluids containing blood, most commonly through injection drug use. With 8-12 weeks of all-oral medication regimens, direct-acting antiviral treatment can result in a virologic cure in most people. This factor is increasing market demand in North America.

HCV infection rates nearly doubled among women with live births in North America between 2009 and 2014, as new HCV infections increased among reproductive-aged adults. As a result, this factor is expected to drive market growth in this region. As per Future Market Insights, North America is likely to account for more than 33.4% of the global Hepatitis C virus testing market in 2023.

Demand for Hepatitis C Virus (HCV) Testing Burgeoning in Europe

Attribute Details
Europe’s Market Share (2022) 30.7%
Germany’s Market Share (2022) 10%
The United Kingdom’s Forecast CAGR (2023 to 2033) 5.7%

In 2023, Europe is forecasted to account for more than 30.7% share in the hepatitis C virus testing market, and is projected to maintain this growth throughout the forecast period, states Future Market Insights.

According to a research paper published in the medical journal BMJ Open in August 2020, HCV diagnosis rates in Germany are projected to exceed 70% by 2030 under the current approach. Such encouraging trends in HCV testing in the country are expected to significantly aid market growth during the forecast period.

In Europe, Hepatitis C is one of the most common infectious diseases. Several initiatives in the region have been inaugurated to better understand disease trends, such as prevalence and the most widely known genotypes. It is a liver disease caused by the hepatitis C virus (HCV), and it can contribute to the development of liver cancer if left untreated.

Germany has historically had a low prevalence of hepatitis C than developing countries. However, the country's demographics have changed in recent years. Also, the increasing influx of migrants and rising drug abuse through injections among the general population are projected to augment the country's hepatitis C prevalence.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-ups Adding Value to the Global Market

The swelling dispersion of start-ups in the hepatitis C virus testing market has improved product quality and elevated global sales. Besides, to gain a competitive edge, new start-ups are working on novel developments and launching new products. Moreover, some notable players offering hepatitis C virus testing kits are as follows:

Start-up’s Name Product in Detail
NATSpert NATSpert, established in 2017 in Pune, India, is a developer of blood detection kits for viral diseases. Its product- NATSpert ID TripleH is a qualitative, real-time PCR test for the simultaneous detection of HIV, HBV, and HCV respectively. The kit comes in a single tube format and allows for screening of HIV type 1 group M-RNA, HIV-1 group-O RNA, HIV-2 RNA, Hepatitis C Virus RNA, and Hepatitis B Virus DNA in human blood plasma.
HepC Founded in 2005, HepC is a developer of antiviral biologic products. The company deploys IBDV, a non-pathogenic double-stranded RNA virus. This virus acts as a master activator of antiviral gene responses as its primary vector system. Its product development includes HC001 for treating advanced chronic viral hepatitis caused by HBV and HCV infections.

Key Players Leading the Hepatitis C Virus Testing Marketplace

Some of the manufacturers identified in the global hepatitis C virus testing market include OraSure Technologies, Inc., Abbott Laboratories Inc., Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Ortho Clinical Diagnostic Inc. (Johnson & Johnson), Bayer AG, QIAGEN N.V., Thermo Fisher Scientific Inc., BioGenex, AccuQuick, Roche Diagnostics (H. Hoffman-La Roche Ltd.), STD Rapid Test Kits, etc. among others.

Discover Recent Occurrences Shaping the Market

Organization’s Name Roche
Nature of Development Roche releases Novel Hepatitis C Virus Diagnostic test.
Key Particulars About the Event Roche has introduced a new dual antibody and antigen diagnostic testing called Elecys HCV Duo immunoassay to treat the hepatitis C virus. The test is launched in countries that permit the CE Mark.
Organization’s Name WHO and the University of BRISTOL
Nature of Development WHO Collaborated with the University of BRISTOL to lead the research related to HCV.
Key Particulars About the Event A new study exhibits the advantages of a quick clinic-based diagnostic test for HCV infection over a general laboratory-based test. The discoveries from the study have resulted in the WHO recommending the adoption of the point-of-care (POC) HCV test. These rapid tests make HCV diagnosis close and accessible to the community.
Organization’s Name Mylab
Nature of Development Pune’s Mylab Introduces Rapid Test Kits to rapidly Detect HCV, HIV, and Syphilis.
Key Particulars About the Event Mylab Discovery Solutions, a Pune-based company, announced in February 2023, that it is releasing three new rapid tests to quickly detect STIs. STIs pose a grave hurdle as WHO predicts that the caseload of STIs is going to reach 1 million/day, globally.
Organization’s Name J MITRA
Nature of Development J MITRA releases 4th Gen Elisa-based HCV Test.
Key Particulars About the Event In September 2022, J Mitra, which is an IVD Company, introduced the HCV Gen 4 Ag & Ab Microlisa, which is a 4th generation Elisa-based HCV Test. The kit aims to screen blood donations to detect and discard infection units of blood. The kit is also used as a clinical diagnostic test for Hepatitis C.
Organization’s Name Access Bio Inc. and Atomo Diagnostics
Nature of Development Access Bio Inc. and Atomo Diagnostics revealed the development of RDT.
Key Particulars About the Event Access Bio Inc. and Atomo Diagnostics announced the development of a rapid diagnostic test (RDT) for screening for the hepatitis C virus in April 2019. (HCV). The tests were commercially available by the end of this year 2019.
Organization’s Name Gilead Sciences Inc.
Nature of Development Gilead Sciences Inc. reported the HepConnect Initiative.
Key Particulars About the Event Gilead Sciences Inc. announced the HepConnect initiative to reduce hepatitis C infections in Great Appalachia in March 2019.

Report Scope

Report Attributes Details
Growth Rate CAGR of 5.4% from 2023 to 2033
Market Value in 2023 US$ 785.3 million
Market Value in 2033 US$ 1,326.7 million
Base Year for Estimation 2022
Historical Period 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Technique
  • End User
  • Test Type
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • OraSure Technologies, Inc.
  • Abbott Laboratories Inc.
  • Siemens Healthcare GmbH
  • Bio Rad Laboratories Inc.
  • Ortho Clinical Diagnostic Inc. (Johnson & Johnson)
  • Bayer AG
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • BioGenex
  • AccuQuick,
  • Roche Diagnostics (F. Hoffman-La Roche Ltd.)
  • STD Rapid Test Kits
Customization Available Upon Request

Key Segments Covered in the Hepatitis C Virus (HCV) Testing Market Survey

By Technique:

  • Immunoassays-based Hepatitis C Virus Testing
  • Polymerase Chain Reaction-based (PCR) Hepatitis C Virus Testing
  • Other Hepatitis C Virus Testing Techniques

By Test Type:

  • HCV Antibody Testing
  • HCV Viral Load Testing
  • HCV Genotyping Testing

By End User:

  • Hospitals
  • Diagnostic Centers
  • Blood Donation Centers

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East & Africa

Frequently Asked Questions

How Big will the the Hepatitis C Virus (HCV) Testing Market?

This market is estimated to reach US$ 1,326.7 million by 2033.

What is North America’s Market Growth Outlook?

North America expanded at a market share of 33.4% in 2022.

What Restrains the Market Growth?

Limited access to regular healthcare restrains the market growth.

Which is the Top Driver in the Market?

Infectious diseases drive sales, hitting global healthcare and developing nations.

Which Region holds Lucrative Opportunities?

North America holds a substantial share of the market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technique

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Technique, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technique, 2023 to 2033

        5.3.1. Immunoassays-based Hepatitis C Virus Testing

        5.3.2. Polymerase Chain Reaction-based (PCR) Hepatitis C Virus Testing

        5.3.3. Other Hepatitis C Virus Testing Techniques

    5.4. Y-o-Y Growth Trend Analysis By Technique, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Technique, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033

        6.3.1. HCV Antibody Testing

        6.3.2. HCV Viral Load Testing

        6.3.3. HCV Genotyping Testing

    6.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033

        7.3.1. Hepatitis C Virus Testing in Hospitals

        7.3.2. Hepatitis C Virus Testing in Diagnostic Centers

        7.3.3. Hepatitis C Virus Testing in Blood Donation Centers

    7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Technique

        9.2.3. By Test Type

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Technique

        9.3.3. By Test Type

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Technique

        10.2.3. By Test Type

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Technique

        10.3.3. By Test Type

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Technique

        11.2.3. By Test Type

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Technique

        11.3.3. By Test Type

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Technique

        12.2.3. By Test Type

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Technique

        12.3.3. By Test Type

        12.3.4. By End User

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Technique

        13.2.3. By Test Type

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Technique

        13.3.3. By Test Type

        13.3.4. By End User

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Technique

        14.2.3. By Test Type

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Technique

        14.3.3. By Test Type

        14.3.4. By End User

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Technique

        15.2.3. By Test Type

        15.2.4. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Technique

        15.3.3. By Test Type

        15.3.4. By End User

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Technique

            16.1.2.2. By Test Type

            16.1.2.3. By End User

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Technique

            16.2.2.2. By Test Type

            16.2.2.3. By End User

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Technique

            16.3.2.2. By Test Type

            16.3.2.3. By End User

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Technique

            16.4.2.2. By Test Type

            16.4.2.3. By End User

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Technique

            16.5.2.2. By Test Type

            16.5.2.3. By End User

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Technique

            16.6.2.2. By Test Type

            16.6.2.3. By End User

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Technique

            16.7.2.2. By Test Type

            16.7.2.3. By End User

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Technique

            16.8.2.2. By Test Type

            16.8.2.3. By End User

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Technique

            16.9.2.2. By Test Type

            16.9.2.3. By End User

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Technique

            16.10.2.2. By Test Type

            16.10.2.3. By End User

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Technique

            16.11.2.2. By Test Type

            16.11.2.3. By End User

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Technique

            16.12.2.2. By Test Type

            16.12.2.3. By End User

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Technique

            16.13.2.2. By Test Type

            16.13.2.3. By End User

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Technique

            16.14.2.2. By Test Type

            16.14.2.3. By End User

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Technique

            16.15.2.2. By Test Type

            16.15.2.3. By End User

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Technique

            16.16.2.2. By Test Type

            16.16.2.3. By End User

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Technique

            16.17.2.2. By Test Type

            16.17.2.3. By End User

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Technique

            16.18.2.2. By Test Type

            16.18.2.3. By End User

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Technique

            16.19.2.2. By Test Type

            16.19.2.3. By End User

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Technique

            16.20.2.2. By Test Type

            16.20.2.3. By End User

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Technique

            16.21.2.2. By Test Type

            16.21.2.3. By End User

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Technique

            16.22.2.2. By Test Type

            16.22.2.3. By End User

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Technique

            16.23.2.2. By Test Type

            16.23.2.3. By End User

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Technique

        17.3.3. By Test Type

        17.3.4. By End User

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. OraSure Technologies, Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Abbott Laboratories Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Siemens Healthcare GmbH

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Bio Rad Laboratories Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Ortho Clinical Diagnostic Inc. (Johnson & Johnson)

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Bayer AG

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. QIAGEN N.V.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Thermo Fisher Scientific Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. BioGenex

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. AccuQuick,

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Roche Diagnostics (F. Hoffman-La Roche Ltd.)

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. STD Rapid Test Kits

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Chronic Hepatitis B Virus Testing Market

March 2023

REP-GB-16778

300 pages

Healthcare

Nipah Virus (NiV) Infection Testing Market

February 2023

REP-GB-16756

292 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Hepatitis C Virus (HCV) Testing Market